Skip to main content

From the Editors

October 2012, Vol 5, No 7
Patrick J. Medina, PharmD, BCOP
Medical Science Liaison
Medical Affairs, GlaxoSmithKline
Collegeville, PA
Adjunct Professor of Pharmacy
University of Oklahoma College of Pharmacy
Steven Stricker, PharmD, MS, BCOP
Assistant Professor of Pharmacy Practice
McWhorter School of Pharmacy
Samford University
Birmingham, AL

In this month’s issue of The Oncology Pharmacist (TOP), we continue our coverage of the news from the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) by addressing the topic of chemotherapy dosing for patients who are obese. In our reader survey poll, we ask you about your experiences in determining the appropriate chemotherapy dose for these patients. Go to and tell us about your experiences with this patient population.

With all the news coming from the ASCO Breast Cancer Symposium, held in September in San Francisco, Cali­for­nia, we present our summary of abstracts of interest to TOP readers. These studies help us keep current about the status of some of the latest research. This is something that Michael P. Kane, RPh, BCOP, of the Cancer Institute of New Jersey, points out when he talks about how quickly the field of oncology pharmacy is changing: “The standard of care is a rapidly moving target, day to day, month to month, and from ASCO to ASCO.” Be sure to read what else Michael has to say in this month’s Cancer Center Profile.

As always, we want to know what you think about TOP. Tell us what topics you want us to cover and give us your feedback—positive and negative. Contact us at This email address is being protected from spambots. You need JavaScript enabled to view it..

Get TOP in Your Inbox

Stay up to date with the latest oncology pharmacy news and insights by subscribing to our e-newsletter!


Related Items